. 2022 Feb 26;49(9):3257–3268. doi: 10.1007/s00259-022-05741-9

Table 2.

Patients’ characteristics stratified by clinical setting

Clinical setting	PSA at PET ng/mL median (IQR)	ISUP ≥ 3% (n)	Positive PSMA-PET % (n)	Pelvic vs systemic recurrence	Oligo- vs multi metastatic
Overall (n = 176)	0.62 (0.43–1.00)	55.1% (97)	39.8% (70)	Pelvic: 17.6% (31) Systemic: 22.2% (39)	Oligo: 34.7% (61) Multi: 5.1% (9)
Subgroup 1 (n = 76)	0.58 (0.36–0.87)	48.7% (37)	27.6% (21)	Pelvic: 14.5% (11) Systemic: 13.2% (10)	Oligo: 25.0% (19) Multi: 2.6% (2)
Subgroup 2 (n = 76)	0.74 (0.5–1.25)	55.3% (42)	48.7% (37)	Pelvic: 21.1% (16) Systemic: 27.6% (21)	Oligo: 40.8% (31) Multi: 7.9% (6)
Subgroup 3 (n = 24)	0.45 (0.37–0.86)	75.0% (18)	50.0% (12)	Pelvic: 16.7% (4) Systemic: 33.3% (8)	Oligo: 45.8% (11) Multi: 4.2% (1)

Clinical setting

PSA at PET ng/mL median (IQR)

ISUP ≥ 3% (n)

Positive PSMA-PET % (n)

Pelvic vs systemic recurrence

Oligo- vs multi
metastatic

Overall

(n = 176)

0.62

(0.43–1.00)

55.1% (97)

39.8% (70)

Pelvic: 17.6% (31)

Systemic: 22.2% (39)

Oligo: 34.7% (61)

Multi: 5.1% (9)

Subgroup 1

(n = 76)

0.58

(0.36–0.87)

48.7% (37)

27.6% (21)

Pelvic: 14.5% (11)

Systemic: 13.2% (10)

Oligo: 25.0% (19)

Multi: 2.6% (2)

Subgroup 2

(n = 76)

0.74

(0.5–1.25)

55.3% (42)

48.7% (37)

Pelvic: 21.1% (16)

Systemic: 27.6% (21)

Oligo: 40.8% (31)

Multi: 7.9% (6)

Subgroup 3

(n = 24)

0.45

(0.37–0.86)

75.0% (18)

50.0% (12)

Pelvic: 16.7% (4)

Systemic: 33.3% (8)

Oligo: 45.8% (11)

Multi: 4.2% (1)

Subgroup 1 first BCR, Subgroup 2 PSA relapse after prostate-bed SRT, Subgroup 3 BCP after RP